Created using Maxygen’s proprietary MolecularBreeding platform, MAXY-VII is a novel Factor VIIa for the treatment of hemophilia. In July 2008, Maxygen announced the sale of its MAXY-VII program to Bayer HealthCare. View press release

MolecularBreeding™, also known as gene shuffling, is an iterative process of recombination and selection. The products of these recombined genes (proteins) are then screened for the targeted drug properties. This novel platform allows scientists to exploit gene variation that can result in unique drug targets or novel therapeutic protein candidates.

Return to Products | Return to Protein Therapeutics
Return to Robust Pipeline | Return to Science & Technology